FDA On Trial Registries: Manufacturers Should Steer Clear Of Claims

Manufacturers should be cautious about drawing explicit conclusions about the outcome of clinical trials posted on public registries, FDA Division of Drug Marketing, Advertising & Communications Director Tom Abrams told a Pharma Audioconference Oct. 26